Drug intelligence / Profile preview

D3126

Development stage: Unknown
Lead developer: Bostal Pharma
Modality: Small Molecules
Administration: Intramuscular

Overview

D3126 is a long-acting injectable (LAI) formulation of brexpiprazole, an atypical antipsychotic, developed by Bostal LLC (formerly AustarPharma) using the 505(b)(2) regulatory pathway. It is intended for the treatment of schizophrenia and agitation associated with dementia due to Alzheimer's disease. The product is designed to provide extended therapeutic coverage, including a 7-month dosing option (D3126 LAI 7M), to enhance patient adherence compared to daily oral medications. Brexpiprazole's mechanism of action involves partial agonism at dopamine D2 and serotonin 5-HT1A receptors, and antagonism at serotonin 5-HT2A receptors.

Other names: Brexpiprazole LAI

Targets

DRD3 (Dopamine receptor D3)HTR2A (Serotonin receptor 5-HT2A)HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))DRD2 (Dopamine D2 Receptor)

Beyond the preview

Go deeper on D3126.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on D3126.

Explore the full profile